CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) (7), especially those targeting the PD-1/PD-L1 pathway, have revolutionized the treatment of advanced melanoma by effectively blocking critical immune escape mechanisms within the tumor microenvironment thus restoring the antitumor activity of T cells (8).